HDAC 抑制剂通过抑制 Hippo/YAP 信号通路来增强骨髓瘤细胞对 Etoposide 的化学敏感性
Zhijie Cao1, Yulu Chen1, Mengshan Chen1,2
1National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
International journal of molecular sciences
|September 27, 2025
概括
基因组脱乙酶抑制剂 (HDACis) 与埃托波 (VP16) 结合,通过增加细胞死亡和减少细胞增殖,增强骨髓瘤治疗. 这种组合针对Hippo/YAP通路,为抗化学抵抗性骨癌提供了潜在的策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 骨髓瘤是一种常见于儿童和青少年的侵袭性骨癌.
- 化学抵抗,特别是在转移或复发的病例中,是一个重大的临床挑战.
- 基质脱乙酶抑制剂 (HDACis) 显示出增强抗癌疗法的潜力.
研究的目的:
- 为了研究HDACis和etoposide (VP16) 对骨髓瘤的联合作用.
- 评估对细胞活力,生长,细胞亡和蛋白质表达的影响.
- 阐明潜在的分子机制,包括Hippo/YAP途径.
主要方法:
- 用HDACis和/或VP16治疗U2OS和SJSA-1骨髓瘤细胞系的治疗.
- 评估细胞活力,形态,生长和亡.
- 使用RNA测序,RT-qPCR和西方布洛特的蛋白质表达和信号通路的分析.
主要成果:
- 无论是HDACis还是VP16,都单独表现出抗增殖作用.
- 在骨髓瘤细胞中,HDACis显著增强了VP16的敏感性,增加了亡.
- VP16/HDACi组合抑制了细胞活力和增殖,比多克索鲁比辛更有效.
- 这种疗法通过减少YAP1蛋白表达来抑制Hippo/YAP信号级联.
结论:
- 在骨髓瘤中,HDAC可增强VP16的抗癌作用.
- 组合疗法降低了Hippo/YAP通路的调节,促进了亡.
- 这种方法提供了一种有前途的策略,以克服骨髓瘤的化学抵抗.
相关概念视频
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
PI3K/mTOR/AKT Signaling Pathway
5.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.4K
The JAK-STAT Signaling Pathway
12.1K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
12.1K
Regulation of Angiogenesis and Blood Supply
3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K


